Countervail Corporation


Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity.

Preclinical laboratory studies demonstrate that AverTox administered by intramuscular injection prior to exposure to a lethal dose of the nerve agent soman, produce significantly better survival than with conventional care drugs alone. Following these studies, Countervail was awarded an additional $845,000 to continue research and development in part to demonstrate oral dosing efficacy of the drug.